EUVIMEDEUVIMED entdecken
Crossref

The Real-World Safety Profile of Hydroxyprogesterone: A Pharmacovigilance Study Based on the Food and Drug Administrationʼs Adverse Event Reporting System Database

Likun Ding iD, Danjun Ren, Meiyou Liu, Juanli Zhang, Di Zhang, Tingting Fan, Yuan Fang

Drug Research · 01.09.2026 · 76 (07) · 163-169

DOI: 10.1055/a-2877-4087 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Research, erschienen am 01.09.2026. Verfasst von Likun Ding und 6 weiteren Autor:innen. Beteiligte Einrichtung: Xijing Hospital, the Fourth Military Medical University, Department of Pharmacy, China, Xi`an. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Pharmacovigilance, Hydroxyprogesterones, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to explore the spectrum of adverse events associated with hydroxyprogesterone and provide a comprehensive understanding of the drug’s safety profile based on the Food and Drug Administrationʼs Adverse Event Reporting System database. Adverse events associated with hydroxyprogesterone were extracted from the Food and Drug Administrationʼs Adverse Event Reporting System database, covering the period from the first quarter of 2004 to the second quarter of 2025. Disproportionality analysis methods were used to detect potential safety signals related to hydroxyprogesterone. We further analyzed the demographic characteristics of the population and the onset time of adverse events. A total of 40,450 adverse event reports related to hydroxyprogesterone were included, corresponding to 197 significant preferred terms categorized into 21 system organ classes per Medical Dictionary for Regulatory Activities criteria. In addition to commonly observed adverse events, several clinically relevant adverse events not previously documented were identified, including fetal distress syndrome, abnormal fetal heart rate deceleration, neonatal jaundice, neonatal respiratory distress, and low birth weight infant. The median time to the onset of hydroxyprogesterone-induced adverse events was 20 days (interquartile range: 0–72 d), with 57.8% of adverse events occurring within the initial 30 days following hydroxyprogesterone administration. In this study, we identified both clinically observed adverse events and potential safety signals associated with hydroxyprogesterone. These results provide valuable evidence to support clinical monitoring, safety risk identification, and the development of subsequent safety investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsPharmacovigilanceHydroxyprogesteronesDrug-Related Side Effects and Adverse ReactionsHumansUnited States Food and Drug AdministrationUnited StatesDatabases, FactualFemale

Substanzen

Hydroxyprogesterones

Autor:innen und Institutionen

  • Xijing Hospital, the Fourth Military Medical University, Department of Pharmacy, China, Xi`an.
  • Xijing Hospital, the Fourth Military Medical University, Department of Respiratory Medicine, China, Xi`an.

ORCID-Profile: Likun Ding

Zitieren

APA

Ding, L., Ren, D., Liu, M., Zhang, J., Zhang, D., Fan, T., & Fang, Y. (2026). The Real-World Safety Profile of Hydroxyprogesterone: A Pharmacovigilance Study Based on the Food and Drug Administrationʼs Adverse Event Reporting System Database. Drug Research, 76(07), 163-169. https://doi.org/10.1055/a-2877-4087

Vancouver

Ding L, Ren D, Liu M, Zhang J, Zhang D, Fan T, et al. The Real-World Safety Profile of Hydroxyprogesterone: A Pharmacovigilance Study Based on the Food and Drug Administrationʼs Adverse Event Reporting System Database. Drug Research. 2026;76(07):163-169. doi:10.1055/a-2877-4087

BibTeX
@article{Ding2026,
  author = {Ding, Likun and Ren, Danjun and Liu, Meiyou and Zhang, Juanli and Zhang, Di and Fan, Tingting and Fang, Yuan},
  title = {The Real-World Safety Profile of Hydroxyprogesterone: A Pharmacovigilance Study Based on the Food and Drug Administrationʼs Adverse Event Reporting System Database},
  journal = {Drug Research},
  year = {2026},
  volume = {76},
  number = {07},
  pages = {163--169},
  doi = {10.1055/a-2877-4087}
}
Kostenlos starten →